CV Stock — CapsoVision, Inc. Common Stock

CapsoVision, Inc. Common Stock (CV)

Updated October 16, 2026.

CV is a Stock. Total return is 86.6% over the past 1.3 years, 61.9 points ahead of SPY at 24.7%.

CapsoVision is a medical technology company that manufactures and markets capsule endoscopy systems for imaging the gastrointestinal tract, including its CapsoCam Plus for small bowel visualization and CapsoCam Colon for colon imaging, along with associated software and data access solutions sold primarily through distributors to medical practices and hospitals. The company does not currently have a stated distribution frequency. This stock appeals to investors interested in medical device manufacturers rather than income-focused investors.

CV performance versus SPY

Price and return data through 2026-10-16.

Total return is 86.6% over the past 1.3 years, 61.9 points ahead of SPY at 24.7%. Its deepest 1-year drawdown was 67.8%.

CV key facts

Asset type

Stock

Asset class

Equity

Inception date

07/02/2025

Distribution frequency

None

Last close

$6.53 (as of 2026-10-16)

Market cap

$347,463,631

Average volume

160776.0

Payout ratio

0.0%

EPS

$-0.45

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CV risks and drawbacks

The deepest 1-year drawdown on record here is 67.8%.

Who may consider CV — and who may not

It is a weaker fit for investors who need monthly cash flow (CV does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on CV

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions